Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL3748554

CCCCCCCCCCCCCC(=O)O.CCCC[N+](CCCC)(CCCC)CCCC

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.77
PPARG P37231 7/20 0.77
PPARD Q03181 7/20 0.77
PPARA Q07869 7/20 0.77
HDAC11 Q96DB2 5/20 0.77
TSHR P16473 4/20 0.77
PTPN1 P18031 3/20 0.77
FABP4 P15090 3/20 0.77
ALDH1A1 P00352 2/20 0.77
TLR2 O60603 2/20 0.77
TDP1 Q9NUW8 2/20 0.77
KMT2A Q03164 2/20 0.77
ALOX15 P16050 2/20 0.77
HSD17B10 Q99714 2/20 0.77
SLC22A6 Q4U2R8 1/20 0.77
SLC22A8 Q8TCC7 1/20 0.77
MEN1 O00255 1/20 0.77
ESR1 P03372 1/20 0.77
PDE4A P27815 1/20 0.77
PDE3A Q14432 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL17101371 1.00 GPR84 (0.77) GPR84PPARGPPARDPPARAHDAC11
Stearic Acid SCHEMBL109144 1.00 GPR84 (0.77) GPR84PPARGPPARDPPARAHDAC11
Tetrabuthylammonium SCHEMBL8778048 1.00 GPR84 (0.77) GPR84PPARGPPARDPPARAHDAC11
Tetrabuthylammonium SCHEMBL1716194 1.00 GPR84 (0.77) GPR84PPARGPPARDPPARAHDAC11
Tetrabuthylammonium SCHEMBL2230012 1.00 GPR84 (0.77) GPR84PPARGPPARDPPARAHDAC11
Tetrabuthylammonium SCHEMBL28280586 1.00 GPR84 (0.77) GPR84PPARGPPARDPPARAHDAC11
Tetrabuthylammonium SCHEMBL2230705 1.00 GPR84 (0.77) GPR84PPARGPPARDPPARAHDAC11
Palmitic Acid SCHEMBL5152853 1.00 GPR84 (0.77) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL5535683 0.98 GPR84 (0.74) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL5533401 0.98 GPR84 (0.74) GPR84PPARGPPARDPPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116672460-A Polyvanadate-based compound capable of resisting obesity and reducing obesity-related inflammation, and preparation and application thereof 华南理工大学 2023-09-01 CN claimed
CN-116672460-A Polyvanadate-based compound capable of resisting obesity and reducing obesity-related inflammation, and preparation and application thereof 华南理工大学 2023-09-01 CN disclosed
CN-110352229-A Semiconductor nano material 默克专利股份有限公司 2019-10-18 CN disclosed
WO-2018146120-A1 SEMICONDUCTOR NANOSIZED MATERIAL MERCK PATENT GMBH (DE) 2018-08-16 WO disclosed
US-20170096614-A1 HALOGEN FREE IONIC LIQUIDS AS LUBRICANT OR LUBRICANT ADDITIVES AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-04-06 US disclosed
US-8426625-B2 Bis-platinum complexes with antitumor activity CELL THERAPEUTICS, INC. (US) 2013-04-23 US disclosed
US-20100292322-A1 Bis-Platinum Complexes With Antitumor Activity CELL THERAPEUTICS, INC. 2010-11-18 US disclosed
EP-1968991-A1 BIS-PLATINUM COMPLEXES WITH ANTITUMOR ACTIVITY Sede Secondaria Della Cell Therapeutics, Inc. (IT) 2008-09-17 EP disclosed
EP-1862329-A1 Ink jet recording material and method of producing ink jet recording material OJI PAPER CO., LTD. (JP) 2007-12-05 EP disclosed
WO-2007071415-A1 BIS-PLATINUM COMPLEXES WITH ANTITUMOR ACTIVITY CELL THERAPEUTICS, INC. - SEDE SECONDARIA (IT) 2007-06-28 WO disclosed
CN-1891764-A Composite fine particles, dispersion, method of producing dispersion, ink jet recording material, and method of producing ink jet recording material OJI PAPER CO (JP) 2007-01-10 CN disclosed
US-20070003716-A1 Composite fine particles, dispersion, method of producing dispersion, ink jet recording material, and method of producing ink jet recording material OJI PAPER CO., LTD. (JP) 2007-01-04 US disclosed
EP-1739136-A1 Composite fine particles and ink jet recording material containing these particles. OJI PAPER CO., LTD. (JP) 2007-01-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292322-A1 Bis-Platinum Complexes With Antitumor Activity IDH3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1 GPR84 4253/4885PPARG 1538/4885PPARD 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.